As ZJ01 is an effective Keap1–Nrf2 PPI inhibitor, we speculated ZJ01 might inhibit LPS-induced cardiomyopathy through disrupting Keap1–Nrf2 PPI which could induce Nrf2 nuclear accumulation and thus blocking oxidative and inflammatory signalling. Here, NFE2L2 is linked to cardiomyopathy.